艾迪药业：注射用ADB116获得《药物临床试验批准通知书》

Group 1 - The core point of the article is that Aidi Pharmaceutical has received approval from the National Medical Products Administration to conduct clinical trials for its new drug ADB116, which is a modified chemical drug [1] - Aidi Pharmaceutical's revenue composition for the year 2024 is as follows: 71.59% from drug manufacturing, 27.07% from biopharmaceutical raw materials, 0.8% from medical devices, and 0.54% from other businesses [1] - As of the report date, Aidi Pharmaceutical has a market capitalization of 5.9 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated $80 billion in overseas licensing this year, indicating a vibrant secondary market for biopharmaceuticals [1] - There is a discussion on the contrasting situation in the primary market, where fundraising has encountered challenges despite the active secondary market [1]